Pazopanib is an oral multi-targeted tyrosine kinase inhibitor that directly targets receptor tyrosine kinases (RTKs), vascular endothelial growth factor (VEGFR) 1/2/3, platelet-derived growth factor (PDGFR) α/β and KIT, thereby blocking tumour growth and inhibiting angiogenesis [30]. This evidence concerns the gene VEGFA and neoplasm.